RMTI ROCKWELL MEDICAL, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1041024 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.0%
TTM net income YoY-2.5%
TTM EPS YoY95.2%
Revenue 3-yr CAGR-3.5%
Net income 3-yr CAGR—
Margins
Gross margin18.1%
Operating margin-7.1%
Net margin-7.8%
FCF margin1.1%
EBITDA margin-4.6%
Returns
ROE-16.1%
ROA-9.9%
ROIC (approx.)-12.8%
Asset turnover1.27x
Leverage & solvency
Liabilities / assets42.0%
Debt / equity0.27x
Current ratio2.47x
Interest coverage-4.56x
Cash quality & payout
Operating cash flow / net income-0.47x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $69.26M | $101.49M | $83.61M | $72.81M | $61.93M |
| Cost of revenue | $57.56M | $84.00M | $74.91M | $68.73M | $64.35M |
| Gross profit | $11.70M | $17.48M | $8.70M | $4.08M | -$2.42M |
| R&D expense | $0 | $19,000 | $1.11M | $3.12M | $6.83M |
| SG&A expense | $14.03M | $14.11M | $12.14M | $15.64M | $15.35M |
| Operating income | -$4.69M | $608,000 | -$6.67M | -$16.78M | -$30.34M |
| Interest expense | $1.12M | $1.25M | $2.30M | $1.94M | $2.36M |
| Pretax income | -$5.31M | -$480,000 | -$8.44M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.31M | -$480,000 | -$8.44M | -$18.68M | -$32.67M |
| EBITDA | -$2.50M | $2.79M | -$5.23M | -$16.20M | -$29.67M |
| EPS (basic) | -0.15 | -0.03 | -0.37 | -1.31 | -3.83 |
| EPS (diluted) | -0.15 | -0.03 | -0.37 | -1.31 | -3.83 |
| Weighted avg. shares (diluted) | 35.97M | 31.06M | 23.32M | 14.30M | 8.53M |
| Balance sheet | |||||
| Cash & equivalents | $10.71M | $15.66M | $8.98M | $10.10M | $13.28M |
| Short-term investments | $14.29M | $5.94M | $1.95M | $11.39M | $9.16M |
| Receivables | $8.14M | $8.29M | $10.90M | $6.26M | $5.91M |
| Inventory | $3.42M | $5.78M | $5.87M | $5.81M | $4.08M |
| Current assets | $38.16M | $37.03M | $28.77M | $35.31M | $35.29M |
| PP&E, net | $4.63M | $5.79M | $6.40M | $2.19M | $2.49M |
| Goodwill | $921,000 | $921,000 | $921,000 | $921,000 | $921,000 |
| Intangibles | $9.66M | $10.21M | $10.76M | $0 | — |
| Total assets | $57.15M | $59.21M | $52.17M | $46.63M | $48.57M |
| Current liabilities | $9.58M | $14.09M | $16.64M | $17.69M | $20.97M |
| Short-term debt | $0 | — | $0 | $1.63M | $7.38M |
| Long-term debt | $8.83M | $8.47M | $8.29M | $7.55M | $13.19M |
| Total debt | $8.83M | $8.47M | $8.29M | $9.19M | $20.57M |
| Total liabilities | $20.16M | $26.62M | $30.88M | $32.53M | $46.04M |
| Shareholders' equity | $36.98M | $32.59M | $21.29M | $14.11M | $2.54M |
| Net debt | -$1.89M | -$7.19M | -$690,000 | -$916,000 | $7.29M |
| Shares outstanding | 3.94M | 34.06M | 29.13M | 12.16M | 8.54M |
| Cash flow statement | |||||
| Operating cash flow | -$659,000 | $4.20M | -$9.41M | -$16.93M | -$33.53M |
| Capital expenditure | $542,000 | $1.01M | $284,000 | — | — |
| Free cash flow | -$1.20M | $3.19M | -$9.70M | — | — |
| Investing cash flow | -$8.54M | -$4.87M | -$3.04M | -$2.40M | $311,000 |
| Financing cash flow | $4.25M | $7.35M | $11.34M | $16.15M | -$2.18M |
| Depreciation & amortization | $2.19M | $2.18M | $1.44M | $576,000 | $668,000 |
| Stock-based compensation | $1.82M | $1.29M | $932,000 | $315,000 | $943,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.